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ABSTRACT
Reducing the frequency of peritonitis for patients under-
going peritoneal dialysis (PD) continues to be a challenge.
This review focuses on recent updates in catheter care and
other patient factors that influence infection rates. An
experienced nursing staff plays an important role in teach-
ing proper PD technique to new patients, but nursing
staff must be cognizant of each patient’s unique educa-
tional needs. Over time, many patients become less adher-
ent to proper dialysis technique, such as washing hands
or wearing a mask. This behavior is associated with
higher risk of peritonitis and is modifiable with re-train-
ing. Prophylactic antibiotics before PD catheter placement
can decrease the infection risk immediately after catheter
placement. In addition, some studies suggest that prophy-
laxis against fungal superinfection after antibiotic expo-
sure is effective in reducing fungal peritonitis, although
larger randomized studies are needed before this practice
can be recommended for all patients. Over time, exit site
and nasal colonization with pathogenic organisms can
lead to exit-site infections and peritonitis. For patients
with Staphylococcus aureus colonization, exit-site prophy-
laxis with either mupirocin or gentamicin cream reduces
clinical infection with this organism. Although there are
limited data for support, antibiotic prophylaxis before
gastrointestinal, gynecologic, or dental procedures may
also help reduce the risk of peritonitis.
Peritonitis for patients treated with peritoneal
dialysis (PD) continues to be a common cause of
PD technique failure, hospitalization, and mortality.
Although certain advancements in technology, such
as the Y-set tubing with flush-before-filling tech-
nique, have been associated with lower peritonitis
rates (1), there is still significant variation in the
infection rates between different programs (2). This
variability, probably driven by differences in prac-
tice patterns, can be viewed as an opportunity for
improvement by understanding risk factors for peri-
tonitis, and interventions that can mitigate that risk.
Several recent review articles published on dialysis-
related peritonitis (3,4) have provided a broad
overview; therefore, our goal was to focus on two
aspects, education and catheter care, which may
provide a high yield in reducing the risk of develop-
ing peritonitis with measurable results at the
program level in a relatively short period of time.
Education & Other Patient Factors
Success of initial training for PD is dependent on
the unique interplay between patient and nurse,
each bringing important variables to the equation.
Social factors and attitudes toward their treatment
that may impact patients’ ability to learn include
both their socioeconomic status and education level.
In a retrospective observational study of incident
PD patients, Chow et al. reported that lower socio-
economic status, as measured by reliance on social
security, was associated with a >2-fold increased
likelihood of developing peritonitis (RR = 2.69;
95% confidence interval: 1.10–6.54) (5). In a larger
multicenter prospective study from Brazil that
included 2032 patients followed up for a median of
12 months, a lower education level, including illiter-
acy, conferred a higher risk of developing peritonitis
even after adjusting for family income, which was
not independently associated with infection (6).
While these factors are not typically modifiable,
understanding the unique socioeconomic factors of
each patient will help the nurse tailor the educa-
tional program in content, length, and approach.
Several studies have evaluated nursing experience
level as it relates to subsequent development of peri-
tonitis. One of the first reports noted that patients
who were trained by nurses with more experience
had higher rates of Gram-positive peritonitis com-
pared with nurses with less experience (7). Whether
this paradoxical finding is related to differences in
educational approach, complexity, and comorbidity
of patients (with more difficult patients being
assigned to more experienced nurses), or other fac-
tors is not possible to determine, given the retro-
spective nature of the study. A more recent study
by Yang et al. (8) reported that being trained by
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PD nurses with more prior experience in general
medicine was associated with a decreased risk of
gram-positive peritonitis, but not all-cause peritoni-
tis when compared with nurses with less experience.
In this observational cohort of 305 incident PD
patients, the peritonitis rates were 1 episode in 45.8,
52.8 and 70.3 months for the least, moderate, and
most experienced nursing groups, respectively. The
authors suggest that the communication and coun-
seling skills of more experienced nurses may play a
role in their findings as the level of PD-specific
nursing experience was similar between groups, and
both studies underscore the complexity of training
patients to perform peritoneal dialysis safely.
While there is a paucity of data on different train-
ing regimens for PD patients and the subsequent
effect on peritonitis rates, it is clear that over time,
many patients alter their dialysis procedure. A mul-
ticenter Italian study (9) of 353 prevalent PD
patients evaluated patient knowledge with a survey
and then a subset of 191 patients had an in-home
visit with evaluation of their exchange technique.
The authors reported that the relative risk for
peritonitis between noncompliant and compliant
patients was 1.6 (95% CI: 1.1–2.4). Specifically, dur-
ing the home evaluation, 9% did not wear a mask,
6% did not wash hands, and 8% had a break in
hygiene during the exchange procedure.
A much larger proportion of nonadherence to
technique was noted in the prospective observa-
tional study by Dong et al. (10) who studied
whether improper bag exchange predicts the first
episode of peritonitis. The study included 130 inci-
dent CAPD patients and found that 6 months after
starting PD, 51% of patients did not wash their
hands properly, and 27% either did not wear a face
mask and cap, or failed to fully cover their nose
and hair. Failure to wear a face mask or cap was
associated with an over 5-fold increased risk of
peritonitis.
Similar results were reported in a smaller study of
30 CAPD patients (11). Using a structured check
list for evaluation, patients with peritonitis in the
prior year were found to have either poor or aver-
age technique, compared with patients with good
technique. Of the poorly compliant patients, 40%
developed peritonitis more than once and common
steps that were missed or performed incorrectly
included not putting on a mask, not washing hands,
and not flushing the tubing. Based on these studies,
it has been observed that some patients become
lax in their dialysis technique over time and that
change in behavior is associated with an increased
risk of peritonitis.
Two components of the dialysis procedure noted
above, wearing a mask and hand washing, have
been studied in additional detail. While it would
seem intuitive that wearing a mask could decrease
the risk of contamination from respiratory and oral
flora, a Brazilian study (12) found no benefit of
wearing a mask during the exchange. Of note, this
study had only 64 patients, used historical controls,
and had a relatively high overall peritonitis rate
(0.94–1.0 episodes per patient year). Interestingly, in
the group that wore a mask, there were no episodes
of peritonitis attributable to Streptococcus viridans
(a pathogen with a presumed oral source), but that
group had a higher rate of infection with Staphylo-
coccus aureus (presumed touch-contamination) with
36% of episodes compared to 10% of episodes
(p < 0.01) in the no-mask group.
Hand hygiene has been previously reviewed in
detail (13), although a few points deserve additional
discussion. With appropriate hand washing, rinsing,
and drying, the number of bacteria that translocate
after a touch-contamination is dramatically reduced
(14). In a carefully performed study with quantita-
tive cultures of microorganisms, Miller et al. dem-
onstrated that with unwashed hands, fewer than
100 organisms translocated from fingers to the
connector set spike after a touch-contamination epi-
sode. However, if the hands were washed, but not
dried, up to 4500 organisms were recovered from
the connector set spike. While there are inconsistent
results about the best method to dry hands after
washing, washed and dried hands reduced the num-
ber of bacteria transferred by touch-contamination
by 95–99%(14), highlighting the need for thorough
hand drying. Wearing rings during hand-washing,
untrimmed fingernails, and artificial nails have all
been associated with higher bacterial counts,
although none of these factors have been directly
associated with an increased risk of peritonitis (15).
Given that soap and water are not typically avail-
able at the time of disconnecting from cycler-based
PD therapy, alcohol-based gels may be used as an
acceptable alternative. The alcohol concentration
should be at least 60% and should be applied for
15–30 seconds and allowed to dry completely (13).
When patients alter the dialysis technique by
omitting key steps, such as not washing hands or
wearing a mask, it would seem that retraining is
necessary. There are very few studies, however, that
evaluate the effect of retraining on improving peri-
tonitis rates. One such study by Gadola et al. (16)
evaluated the effect of a multidisciplinary PD
education program on peritonitis rates. Part of this
program included routine use of retraining twice
annually, and stressed safe bag exchange procedures
at each monthly clinic visit. With this education
program, peritonitis rates declined significantly from
0.55 episodes per patient-year to 0.28 episodes per
patient-year and Staphylococcus peritonitis rates in
particular declined as well. Unfortunately, it is diffi-
cult to discern the relative impact of the initial
training program from the re-training component.
An Italian multicenter observational study also
noted a reduction in peritonitis rates associated with
predialysis training, home visits, and retraining (17).
Additional study is clearly needed to determine the
effect of retraining on peritonitis rates, as well as
which specific components of the exchange
procedure need reinforcement. Until such data are
available, periodic retraining done after the first
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6 months of PD and then at least yearly would
seem prudent.
Antibiotics before Catheter Placement
In the general surgical literature, preoperative
antibiotic prophylaxis is usually not recommended
for clean procedures, unless a foreign body is being
inserted. This rationale led experts in the dialysis
community to recommend use of preoperative anti-
biotics for peritoneal dialysis catheter placement,
even before there was evidence to support the prac-
tice (18). Over the ensuing decade, several random-
ized single-center studies were published describing
the effect of antibiotic prophylaxis prior to perito-
neal dialysis catheter placement (19–21). Two of
three studies demonstrated reduction in postplace-
ment peritonitis.
Gadallah reported results of a prospective, ran-
domized, open-label longitudinal study of 221
patients undergoing 254 peritoneal dialysis catheter
placements (22). Patients were randomized to a sin-
gle dose of iv vancomycin 12 hours prior to catheter
placement, or a single iv dose of cefazolin 1000 mg
3 hours prior to catheter placement, or no antibiotic
treatment. Perioperative peritonitis occurred in 1%
of vancomycin-treated patients, 7% of cefazolin-
treated patients, and 12% of patients without pre-
operative prophylactic antibiotics. Overall, of the 17
peritonitis episodes identified, 13 were associated
with Gram-positive organisms, 3 were culture-nega-
tive, and 1 grew Enterobacter cloacae. Relative to
the vancomycin-treated group, the odds ratio of
peritonitis was 6.45 (CI: 0.76–54.8) and 11.64 (CI:
1.46–93.14) in the cefazolin-treated and untreated
groups, respectively.
More recent guidelines from the Renal Associa-
tion Working Party on Peritoneal Access (www.
renal.org) and International Society of Peritoneal
Dialysis (ISPD) recommend preoperative prophylac-
tic antibiotics prior to peritoneal dialysis catheter
placement (3, 23). The ISPD recommendations state
that prophylactic antibiotics administered at the
time of insertion decrease the infection risk, and
suggest that “…centers consider the use of vanco-
mycin for prophylaxis for catheter placement, care-
fully weighing the potential benefit against the risk




In the 25 years since publication of the first rec-
ommendations for peritonitis prevention (18), the
importance of the peritoneal dialysis catheter exit
site and S. aureus carrier status of patients in the
development of bacterial peritonitis and catheter
loss has changed dramatically, reflected in recent
recommendations from the ISPD that all PD
patients should use topical antibiotic either at the
catheter exit site daily or intranasally or both (3).
Impact of Nasal Colonization and Exit-Site
Colonization/Infection
An early single-center observational study demon-
strated the association between history of exit-site
infection (ESI) and subsequent peritonitis. In addi-
tion, history of ESI was closely associated with sub-
sequent catheter removal, illustrating the clinical
impact of infectious complications on peritoneal
catheter survival (24). Several subsequent studies
confirmed the clinical association between ESI
and subsequent peritonitis, particularly for ESI in
which S. aureus was identified. Davies et al.
described their center’s historical experience with
S. aureus peritonitis and identified a strong
association between peritonitis with this organism
and ESI with S. aureus (25). Overall, approximately
50% of S. aureus peritonitis episodes were associ-
ated with S. aureus ESI. For those patients with
relapsing S. aureus peritonitis, 100% had associated
S. aureus ESI. In the same report, the investigators
describe a prospective evaluation of nasal carriage
in 87 prevalent peritoneal dialysis patients. Twenty-
seven of 87 (31%) patients were S. aureus carriers.
Nasal carriage was present in 20 individuals (23%),
fourteen (70%) of whom were culture-positive for
S. aureus at the peritoneal catheter exit site in addi-
tion to the nares. In addition, seven individuals had
S. aureus exit-site colonization without evidence of
nasal carriage. The S. aureus carrier state manifest
as both nasal and exit-site colonization in roughly
one-half of carriers; one-quarter of patients were
only nasal carriers and another one-quarter of
patients only exit-site carriers.
In 1990, Luzar reported results of a prospective,
multicenter study of S. aureus carrier status in inci-
dent peritoneal dialysis in seven European hospital
centers (26). One hundred forty patients underwent
nasal swab culture for S. aureus isolation before PD
catheter placement. Overall, 63% carried S. aureus
in the nares, with a significantly higher carriage rate
in the diabetic patients compared with nondiabetics
(77% vs. 36%). Over a median 10 months’ follow-
up, the S. aureus carriers had a significantly higher
rate of ESI (0.4 vs. 0.1 episode per year). The
majority of ESIs were caused by S. aureus. Overall
peritonitis rates did not differ between carriers
and noncarriers, but all documented episodes of
S. aureus peritonitis occurred in individuals with
confirmed S. aureus nasal carriage before PD
catheter placement.
As part of a single-center, prospective study of
thrice-weekly low-dose oral trimethoprim/sulfa-
methoxazole versus no prophylaxis to prevent ESI
and peritonitis reported by Swartz, et al., exit-site
culture was obtained when patients presented with
peritonitis, regardless of whether ESI was identified
clinically (27). Staphylococcus aureus peritonitis was
associated with a positive exit-site culture for
496 Segal and Messana
S. aureus in 85% of cases, and the majority of
patients with S. aureus peritonitis had a clinical
tunnel-ESI infection present at presentation with
peritonitis. Amato et al. studied concordance of
Staphylococcal species isolated from peritonitis
with other sites (fingernails, nares, exit-site, dialysis
partners) (28). Using pulse field gel electrophoresis,
10/14 S. aureus peritonitis episodes were associated
with patient carriage of the same strain of organ-
ism on other body sites. In addition, 5/14
S. aureus peritonitis episodes were associated with
identical S. aureus strain cultured from the
patient’s nares.
A recently published secondary analysis of 203
patients followed up over 18 months during partici-
pation in the “MP3” randomized, interventional
study of two different exit-site prophylaxis strategies
(mupirocin versus Polysporin Triple) was used to
estimate the risk of developing peritonitis in the
30 days after ESI (29). Patients with ESI had a
markedly higher likelihood of developing peritonitis
in the 60 days after ESI. Decreasing risk over time
was noted, and interestingly, only 1 of 7 patients
had the same causative organism identified in both
the ESI and peritonitis. On the surface, these results
seem contradictory to the older literature until one
considers that the study population was undergoing
exit-site prophylaxis with topical antibacterial
agents that reduced the relative incidence of
S. aureus ESI and peritonitis relative to other
organisms.
Strategies to Reduce Exit-site Infection and
Peritonitis
Several interventions have been recommended to
reduce ESI, peritonitis or both in patients on
chronic peritoneal dialysis, including exit-site clean-
ing technique, intranasal mupirocin to reduce
S. aureus carriage, oral antibiotics (trimethoprim-
sulfamethoxazole and rifampin), and topical appli-
cation of anti-infective agents to the catheter exit
site (mupirocin ointment or cream; gentamicin
cream; polysporin ointment). Several reviews and
meta-analyses describe results of these studies,
although a limitation of the available meta-analyses
is that most include historical control cohort studies
in addition to randomized controlled trials (30–33).
In addition, seven randomized controlled trials and
numerous historically controlled cohort or retro-
spective studies have been published informing the
effectiveness of strategies intended to reduce cathe-
ter-related infection (34–45).
Exit-Site Care
Luzar reported results of a randomized, multicen-
ter study (40) of daily exit-site care with nonbacteri-
cidal soap and water versus exit-site care with
povidone iodine every 2–3 days. ESI rate in the
povidone iodine group was 0.27 per patient-year vs.
0.71 (p = 0.0183) per patient-year in the soap and
water group. No significant differences in peritonitis
rates between the two groups were identified. Of
note, the majority of ESI in both groups were
related to S. aureus. There were 15 episodes of
S. aureus ESI in 15 povidone iodine-treated patients
(18 episodes including all organisms) and 16 epi-
sodes of S. aureus ESI in 14 patients treated with
soap and water (24 ESI episodes including all
organisms).
Nasal Mupirocin
The Mupirocin Study Group conducted a multi-
center, double-blind randomized controlled trial of
mupirocin ointment intranasally for five consecutive
days every 4 weeks versus placebo in PD patients
with established S. aureus carrier status (34). A
total of 1144 patients at nine European PD centers
were screened for nasal carriage of S. aureus.
Twenty-four percent were positive and consisted of
the randomization pool of subjects. Nasal carriage
fell to 10% in the mupirocin-treated group com-
pared to 48% in the placebo-treated subjects. Over-
all, ESIs were not significantly reduced in the
mupirocin-treated patients (33/1390 patient-months
vs. 55/1236 patient-months). However, the mupiro-
cin-treated patients experienced significantly fewer
ESIs caused by S. aureus, without differential rates
of tunnel infections or peritonitis in the two groups.
The investigators were not able to demonstrate
development of increasing resistance to mupirocin,
despite actively screening culture isolates for mup-
irocin resistance (both low- and high-level) during
the study period.
Exit-Site Interventions
Several cohort studies evaluating use of topical
antibiotic agents applied to peritoneal dialysis cath-
eter exit sites have reported reduced ESI and or
peritonitis rates, particularly for Gram-positive
organisms compared with historical controls (38,
39, 41, 43, 44). The meta-analysis of mupirocin in
prevention of S. aureus catheter-related infections
by Tacconelli included all English language
published reports of mupirocin in dialysis patients
(hemodialysis [HD] and PD) (32). Randomized
controlled trials and cohort studies of adults were
included, if either placebo-controlled or no therapy
was used for the control group. The primary out-
come of interest was number of S. aureus infec-
tions in mupirocin-treated and untreated patients.
Ten studies met criteria for inclusion. Risk reduc-
tions were 80% and 63% risk reduction for HD
and PD patients, respectively. Both S. aureus peri-
tonitis and ESIs were reduced similarly in the PD
patients included in the meta-analysis. Of note, 5/6
studies of peritoneal dialysis patients were cohort
studies with historical controls. The sole random-
ized controlled trial included in the meta-analysis,
a trial of nasal mupirocin discussed above,
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contributed substantial weight to the outcomes, but
reported similar magnitude and direction outcome
of mupirocin prophylaxis to those of the cohort
studies.
A Cochrane review of randomized controlled tri-
als testing strategies to reduce catheter-related infec-
tions in peritoneal dialysis was published in 2004
(31). Four studies evaluating oral antibiotic prophy-
laxis to prevent peritonitis did not support use of
this strategy. The use of intranasal antibiotics was
shown to reduce exit-site/tunnel infections, but not
peritonitis, based largely on the results of the Mup-
irocin Study Group report (34). Five randomized
controlled trials evaluating topical antibiotics (mup-
irocin, gentamicin cream, or polysporin ointment)
to prevent catheter-related infections in peritoneal
dialysis patients have been published since the
Cochrane review (35–37, 42, 45).
Bernardini reported results of a single-center
randomized, unblinded trial comparing cyclic oral
rifampin versus daily topical mupirocin calcium 2%
ointment to the exit site (36). Similar rates of peri-
tonitis and ESI/tunnel infection were reported with
both therapies. The investigators reported that
catheter infection rates with S. aureus were higher
in the historical period compared with either inves-
tigational treatment. Wong reported results of a
single-center prospective randomized trial of tradi-
tional exit-site care versus daily application of mup-
irocin ointment (45). The mupirocin-treated group
was noted to have a marked reduction in Gram-
positive ESI and peritonitis compared with con-
trols. Infections caused by other organisms and
overall ESI and peritonitis rates were not signifi-
cantly different between the two groups. In 2005,
Bernardini reported results of a multicenter, dou-
ble-blind randomized trial (n = 133 PD patients)
comparing daily mupirocin versus gentamicin cream
to PD catheter exit site (35). Catheter infection
rates were 0.23/patient-year with gentamicin vs.
0.54/patient-year with mupirocin (p = 0.005). Simi-
larly, peritonitis rates were significantly lower in the
gentamicin cream group compared with mupirocin
group (0.34 vs. 0.52 episodes per patient-year
(p = 0.03).
Chu conducted a randomized, open-label, single-
center study of topical gentamicin versus mupirocin
creams in 95 Chinese PD patients (37). Overall, sim-
ilar results were reported with either topical antibi-
otic for both ESI and peritonitis rates. Total
peritonitis rates were 0.33 per patient-year and ESI
infection rates were 0.38 per patient-year. Average
follow-up was 11 months for the gentamicin group
and approximately 14 months for the mupirocin
group.
McQuillan reported results of the MP3 study, the
multicenter, double-blind randomized controlled
trial of mupirocin versus Polysporin Triple ointment
with 18-month designed follow-up (42). The time to
first event was not different between polysporin and
mupirocin groups. Over the study period, higher
rates of both fungal ESI and fungal peritonitis were
seen in the polysporin-treated group. The fungal
peritonitis rate was 0.04 for polysporin group and
0.00 for the mupirocin group.
Mupirocin Resistance
Several concerns have been raised about the
potential consequences of topical mupirocin use,
including catheter biocompatibility and development
of resistance. Early experience with the use of ongo-
ing topical mupirocin to prevent catheter-related
infections in both hemodialysis and peritoneal
dialysis patients had not identified development of
resistance to the agent, despite development of
significant in vitro resistance in some cases associ-
ated with loss of clinical effectiveness reported
among patients in other settings (46–52).
Subsequent reports have described development
of mupirocin resistance in peritoneal dialysis pro-
grams using mupirocin prophylaxis. Perez–Fontan
reported their longitudinal single-center experience
from one Spanish center (53). Beginning in Septem-
ber 2000, topical mupirocin was added to their
exit-site care protocol in response to increasing
S. aureus catheter-related infections. From 1990 to
1996, 5% of S. aureus isolates had low-level mup-
irocin resistance. In 1997 to 1998, 6.6% and 8.3%
of isolates were identified with low- and high-level
mupirocin resistance, respectively. In 1999 and
2000, 2.3% and 12.4% of isolates were identified as
having low- and high-level mupirocin resistance,
respectively. The identification of mupirocin-
resistant S. aureus in patients was associated with
an approximate two-fold higher risk of S. aureus
ESI.
Lobbedez described their results of cross-sectional
surveillance culturing of 147 prevalent chronic peri-
toneal dialysis patients from one Canadian center
(54). The center’s patients had been using mupirocin
for routine exit care for several years prior to the
surveillance culture, regardless of S. aureus carrier
status. Mupirocin resistance was identified in iso-
lates from 25% of the S. aureus carriers. The inves-
tigators include data from prior cross-sectional
surveillance reported in 1999 and 2001. After 1 year
of routine mupirocin use, 0/27 S. aureus carriers
had resistant strains identified. After 4 years of pro-
tocol use, 4/26 S. aureus carriers had mupirocin-
resistant strains. After 7 years of use, 4/16 S. aureus
carriers’ isolates were mupirocin-resistant.
Recommendations
Prevention of ESI and peritonitis in high-risk
peritoneal dialysis patients is important and likely
to impact outcome. Targeting S. aureus and Pseudo-
monas aeruginosa ESI seems particularly important,
considering the high rates of peritonitis and catheter
loss associated with these organisms. Research
describing methods of catheter exit-site care from
other settings and in peritoneal dialysis patients has
demonstrated the importance of inspection and
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exit-site cleansing and disinfection. Daily exit-site
mupirocin application has been shown to be effec-
tive in reducing Gram-positive ESI and peritonitis
episodes in controlled trials and several historically
controlled studies. However, this approach is less
effective in prevention of catheter-related infections
with P. aeruginosa and other Gram-negative organ-
isms. In contrast, gentamicin exit-site prophylaxis
appears to be at least as effective as mupirocin in
overall catheter-related infection prophylaxis and
provides broader coverage than mupirocin alone.
However, on the basis of clinical experience with
mupirocin and the general experience with use of
antibiotics, we anticipate development of increasing
bacterial resistance over time.
Given these considerations, we recommend facility
protocols that reinforce the importance of regular
exit-site inspection and cleansing, with either povi-
done iodine or other antiseptics shown to be effective
in other care settings (e.g., chlorhexidine in alcohol)
as long as the antiseptic agent is compatible with the
catheter. For patients at high risk for S. aureus colo-
nization (e.g., diabetes mellitus present) or with doc-
umented colonization, exit-site prophylaxis with
either mupirocin or gentamicin cream seems prudent.
In immune-compromised patients and in those with
history of P. aeruginosa ESIs, prophylaxis with gen-
tamicin cream may be warranted.
Prophylaxis with Antifungals during Antibiotic
Treatment
Epidemiology of Fungal Peritonitis
Fungal peritonitis, a devastating complication of
peritoneal dialysis, is usually due to infection with
Candida species. Its avoidance is of critical impor-
tance in the care of patients on chronic peritoneal
dialysis. Several factors have been associated with
development of fungal peritonitis including climate,
immunosuppression, and most importantly, prior
exposure to antibiotics (55–58).
Interventions to Prevent Secondary Fungal
Peritonitis
Several prospective cohort studies with historical
controls have been published on the topic of fungal
peritonitis prevention (59–62). Across studies, there
was heterogeneity in patient populations and type
of antifungal prophylaxis used, but most utilized
oral nystatin during periods of antibiotic use as the
primary preventive strategy. Three of four studies
reported significant reductions in antibiotic-associ-
ated fungal peritonitis.
Williams reported a prospective cohort study
using two closely related PD centers in England
(63). One center initiated oral prophylaxis with nys-
tatin 500,000 units PO QID during antibiotic ther-
apy. The other unit continued to treat bacterial
peritonitis without antifungal prophylaxis. Similar
rates of fungal peritonitis were present in the two
units. The authors concluded that there was no
beneficial effect of nystatin prophylaxis in their
patient population (baseline fungal peritonitis rate
of 3.4%). Lo performed a randomized, open-label
single-center study of oral nystatin 500,000 units PO
QID whenever antibiotics were prescribed versus no
therapy in 199 nystatin-treated and 198 control
patients (64). Mean follow-up was 18 months and
16.6 months for nystatin-treated and control sub-
jects, respectively. Patients in the nystatin-treated
group had significantly lower Candida peritonitis
rates at 2 years. The antibiotic-associated Candida
peritonitis rate was not different between the inter-
vention and control groups.
Restrepo reported results of a prospective, ran-
domized single-center open-label trial of fluconazole
200 mg PO every 48 hours in patients receiving
antibiotics for catheter-related infections (65). Seven
percent of all peritonitis developing during the study
period was caused by Candida species. Of those,
approximately 55% were secondary fungal infec-
tions, defined as developing within 30–150 days
after antibiotic exposure. Most of the secondary
peritonitis occurred in the 30–60 day window
(n = 10 of 15 total). Only 3 episodes of secondary
peritonitis occurred in the fluconazole prophylaxis
group. The high basal fungal peritonitis rates make
generalization of this study to other settings poten-
tially problematic.
Recommendations
Based largely on the Restrepo study, we recom-
mend that providers strongly consider use of fungal
prophylaxis with oral fluconazole in centers with
high background fungal peritonitis rates and in
highly immune-compromised patients. Whether oral
nystatin is effective prophylaxis is less clear, given
the lack of consistent results.
Antibiotic Prophylaxis before Gastrointestinal,
Gynecologic, and Dental Procedures
Gastrointestinal symptoms are common in perito-
neal dialysis and both constipation and diarrhea in
particular have been identified as risk factors for
developing peritonitis (66, 67). Based on animal mod-
els, it is believed that intestinal flora may undergo
transmural migration into the peritoneal cavity in the
setting of inflamed serosa (68). A case series of five
patients with Gram-negative or polymicrobial perito-
nitis highlighted that the acute treatment of constipa-
tion with enemas was a common factor in 4 of the 5
patients (69). Hypokalemia has also been associated
with peritonitis and Chuang et al. (70) proposed a
mechanism by which hypokalemia leads to decreased
intestinal motility and subsequent bacterial over-
growth. In addition, hypokalemia is associated with
malnutrition that they propose could lead to
increased bowel wall edema and impaired immuno-
logic function that can predispose to peritonitis. It
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remains unclear whether potassium supplementation
outside of improvement in nutritional status could
decrease the risk of peritonitis.
Finally, in a study of 104 CAPD patients, Yip
and colleagues reported that patients with enteric
peritonitis were more likely to have diverticulosis
compared with those without enteric peritonitis
(38.8% vs. 10.9%, p = 0.001) (71). While a high-
fiber diet may help reduce episodes of diverticulitis
in the general population, it is unknown whether
dietary intervention could reduce the risk of perito-
nitis for those with diverticular disease. While not
an absolute contraindication to PD, patients with
diverticulosis who elect PD as their modality choice
should be counseled about the potential increased
risk of peritonitis.
Based on a number of case reports, the 2005
ISPD guidelines recommend that prophylactic anti-
biotics be given before endoscopic procedures and
this recommendation is reiterated in the 2011 ISPD
position statement on reducing the risk of peritoneal
dialysis-related infections. However, there is only
marginal evidence to support the efficacy of pre-
endoscopic antibiotics. The most comprehensive
data come from a retrospective study of 97 colonos-
copies performed in PD patients (72). The risk of
peritonitis was 6.3% without pre-procedure antibi-
otics, compared to 0% in the 18 cases where antibi-
otics were given ahead of time, although the
difference was not statistically significant likely due
to the small sample size. In addition, of the five
cases of peritonitis, only one was from a docu-
mented enteric organism. Nevertheless, given the
morbidity of peritonitis, pre-endoscopic use of
either IV or intraperitoneal antibiotics is warranted
in an attempt to reduce peritonitis rates, but addi-
tional research would be helpful. Given the variety
of bowel organisms, coverage for Gram-positives
such as enterococcus, Gram-negatives such as
E. coli, and anaerobic organisms such as Bactero-
ides should be considered.
There are several case reports of peritonitis devel-
oping in the wake of gynecologic procedures such
as hysteroscopy (73–75). Although not a common
cause of peritonitis, it may be potentially prevent-
able, similar to other endoscopic-related peritonitis,
with pre-procedure antibiotics as one anecdotal
report indicates (74). An ISPD position statement
recommends that the abdomen be emptied of fluid
before any procedure involving the abdomen or pel-
vis including colonoscopy, renal transplantation,
cholecystectomy, and endometrial biopsy (3).
Transient bacteremia after dental procedures is
common and antibiotic prophylaxis can decrease
the frequency of this event (76). Case reports (77,
78) of peritonitis with Streptococcus viridans fol-
lowing dental procedures suggest that on rare
occasions, this transient bacteremia can seed the
peritoneum and lead to infection. Use of amoxicillin
prior to dental procedures should be considered,
but it is unclear to what extent this intervention is
effective in reducing peritonitis.
Conclusions
Peritonitis continues to be a significant cause of
technique failure for peritoneal dialysis as well as
leading to significant morbidity, hospitalization, and
death. While there are many areas of prevention
that still need additional research, there are steps
that dialysis facilities can take to decrease peritonitis
rates. Experienced nursing staff can play a key role
in patient education which, combined with interval
retraining of patients, may lead to lower peritonitis
rates. Antibiotics given before PD catheter place-
ment can lower peritonitis rates immediately after
the procedure. Regular exit-site care with either top-
ical mupirocin or gentamicin, particularly for those
with S. aureus colonization or who are immuno-
compromised, should be considered. Lastly, pre-
procedure antibiotics may further reduce peritonitis
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